RE:ONCY bispecific in development (pelareorep x CD3)
ONCY's AWARE-1 showed that treatment with pelareorep with (cohort 2) or without (cohort1) atezolizumab led to the conversion of tumors from the more aggressive luminal B to the luminal A subtype, which is associated with improved clinical outcomes
Supplementary to the AWARE-1 findings ONCY's pelareprep X CD3 bispecific has pelareorep binding to CD3 on the surface of T cells which then redirects the immune cells to help eliminate cancerous B cells like those appearing in pancreatic and breast cancer.